Fact CheckerSign in

NCT07779057RecruitingPhase 4

Comparison of High- Versus Low-Dose Aspirin for Pregnancy Outcomes in Women at High Risk of Preeclampsia

High Versus Low Dose Aspirin Effects on Fetomaternal Outcomes in Women With High Risk of Preeclampsia

Source: ClinicalTrials.gov · Last updated 21 Aug 2026

Brief summary (registry, in English)

The goal of this randomized clinical trial is to compare the effects of two doses of aspirin, 75 mg and 150 mg, in pregnant women who are at high risk of developing preeclampsia. The main question the study aims to answer is: 1. Does taking 150 mg of aspirin reduce the occurrence of preeclampsia more effectively than taking 75 mg of aspirin in pregnant women at high risk of preeclampsia? 2. Are there differences in stillbirth and newborn birth weight between the two aspirin doses? The study will include 224 pregnant women aged 18-45 years who are between 11 and 14 weeks of pregnancy and are identified as being at high risk for preeclampsia. Participants will be randomly assigned to one of two groups. * Participants in the low-dose group will take 75 mg of aspirin once daily at bedtime. * Participants in the high-dose group will take 150 mg of aspirin once daily at bedtime. Participants will continue their assigned aspirin dose until 36 weeks of pregnancy and will be followed every 2 weeks until delivery. The study will record whether participants develop preeclampsia and whether stillbirth occurs. The birth weight of each newborn will also be measured within 3 hours of birth. The study hypothesis is that 150 mg of aspirin will result in a lower incidence of preeclampsia than 75 mg of aspirin in pregnant women at high risk of preeclampsia.

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
60 (estimated)
First submitted
18 Aug 2026
Start date
12 May 2026
Primary completion date
11 Nov 2026
Lead sponsor
Medicare Hospital (Pvt) Limited
NCT number
NCT07779057

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 60
  • From 12 May 2026 to the primary completion date, 11 Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Renal disease
  • Vaginal bleeding

Lab values

  • Abnormal coagulation profile (INR \> 1.5)
  • Platelet count \< 150,000/mm\^3

Other

  • Active gastritis
  • Fetal malformations

Who the study is looking for

  • Gestational age 11-14 weeks
  • High risk of preeclampsia

Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Medicare Hospital (Pvt) Ltd.
Coordinator of this site? Confirm its status
MultanPakistanRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.